NRG/RTOG 1112 Study Evaluates SBRT Plus Sorafenib for Hepatocellular Carcinoma
March 22nd 2023Laura A. Dawson, MD, FRCPC, discusses the NRG/RTOG 1112 study for patients with hepatocellular carcinoma which evaluated stereotactic body radiation therapy followed by sorafenib compared with sorafenib alone.